Loading...
•
Sep 30, 2022
RAPT Q3 2022 Earnings Report
RAPT Therapeutics reported financial results for the third quarter of 2022 and maintained a strong cash position.
Key Takeaways
RAPT Therapeutics reported a net loss of $21.2 million for the third quarter of 2022, compared to a net loss of $18.7 million for the same period in 2021. The company's research and development expenses for the third quarter of 2022 were $16.6 million, compared to $15.7 million for the same period in 2021. As of September 30, 2022, the Company had cash, cash equivalents and marketable securities of $195.4 million.
Net loss for the third quarter of 2022 was $21.2 million.
Research and development expenses for the third quarter of 2022 were $16.6 million.
General and administrative expenses for the third quarter of 2022 were $5.1 million.
Company had cash, cash equivalents and marketable securities of $195.4 million as of September 30, 2022.
Forward Guidance
RAPT Therapeutics is focused on executing and advancing both its inflammation and oncology programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...